Maravai LifeSciences Completes Acquisition of the DNA and RNA Business of Officinae Bio
Maravai LifeSciences (NASDAQ: MRVI) has completed its acquisition of Officinae Bio's DNA and RNA business. This acquisition integrates Officinae Bio's AI-enabled mRNA design platforms with Maravai and TriLink BioTechnologies' drug substance manufacturing capabilities, offering comprehensive expertise and novel technologies. This integration aims to accelerate the mRNA sequence-optimization phase and advance clinical testing and commercial manufacturing.
Officinae Bio, based in Venice, Italy, uses a proprietary digital platform to speed up mRNA drug candidate prototyping, facilitating rapid testing of diverse combinations of capping analogs, chemical modifications, and sequence designs. The acquisition will enhance Maravai's capabilities in next-generation medicines, particularly in mRNA and CRISPR, leveraging proprietary technologies like CleanCap® analogs.
This move also marks Maravai's entry into the European market with a manufacturing footprint, expected to drive growth across multiple product lines. Officinae Bio's CEO, Davide De Lucrezia, will continue to lead the team within Maravai’s Nucleic Acid Production segment.
Maravai LifeSciences (NASDAQ: MRVI) ha completato l'acquisizione del business di DNA e RNA di Officinae Bio. Questa acquisizione integra le piattaforme di progettazione mRNA abilitata dall'IA di Officinae Bio con le capacità di produzione di sostanze farmaceutiche di Maravai e TriLink BioTechnologies, offrendo una competenza completa e tecnologie innovative. Questa integrazione mira ad accelerare la fase di ottimizzazione della sequenza mRNA e a promuovere i test clinici e la produzione commerciale.
Officinae Bio, con sede a Venezia, Italia, utilizza una piattaforma digitale proprietaria per velocizzare il prototipaggio dei candidati farmaceutici mRNA, facilitando test rapidi di diverse combinazioni di analoghi di cappucci, modifiche chimiche e progettazioni di sequenze. L'acquisizione migliorerà le capacità di Maravai nei farmaci di nuova generazione, in particolare nell'mRNA e nel CRISPR, sfruttando tecnologie proprietarie come gli analoghi CleanCap®.
Questa mossa segna anche l'ingresso di Maravai nel mercato europeo con una presenza produttiva, che si prevede stimolerà la crescita in diverse linee di prodotto. Il CEO di Officinae Bio, Davide De Lucrezia, continuerà a guidare il team all'interno del segmento di Produzione di Acidi Nucleici di Maravai.
Maravai LifeSciences (NASDAQ: MRVI) ha completado la adquisición del negocio de ADN y ARN de Officinae Bio. Esta adquisición integra las plataformas de diseño de mRNA habilitadas por IA de Officinae Bio con las capacidades de fabricación de sustancias farmacéuticas de Maravai y TriLink BioTechnologies, ofreciendo una experiencia integral y tecnologías novedosas. Esta integración tiene como objetivo acelerar la fase de optimización de secuencias de mRNA y avanzar en las pruebas clínicas y la fabricación comercial.
Officinae Bio, con sede en Venecia, Italia, utiliza una plataforma digital propietaria para acelerar el prototipado de candidatos a medicamentos de mRNA, facilitando pruebas rápidas de diversas combinaciones de análogos de tapa, modificaciones químicas y diseños de secuencias. La adquisición mejorará las capacidades de Maravai en medicamentos de próxima generación, particularmente en mRNA y CRISPR, aprovechando tecnologías propietarias como los análogos CleanCap®.
Este movimiento también marca la entrada de Maravai en el mercado europeo con una huella de fabricación, lo que se espera impulse el crecimiento en múltiples líneas de productos. El CEO de Officinae Bio, Davide De Lucrezia, continuará liderando al equipo dentro del segmento de Producción de Ácidos Nucleicos de Maravai.
Maravai LifeSciences (NASDAQ: MRVI)는 Officinae Bio의 DNA 및 RNA 사업부를 인수 완료했습니다. 이 인수는 Officinae Bio의 AI 기반 mRNA 설계 플랫폼과 Maravai 및 TriLink BioTechnologies의 약물 물질 제조 능력을 통합하여 포괄적인 전문 지식과 혁신적인 기술을 제공합니다. 이 통합은 mRNA 서열 최적화 단계를 가속화하고 임상 시험 및 상업적 제조를 발전시키는 것을 목표로 합니다.
이탈리아 베네치아에 본사를 둔 Officinae Bio는 독자적인 디지털 플랫폼을 사용하여 mRNA 약물 후보의 프로토타입을 신속하게 개발하고, 다양한 캡핑 유사체, 화학적 수정 및 서열 설계의 조합을 신속하게 테스트합니다. 이 인수는 Maravai의 차세대 의약품, 특히 mRNA 및 CRISPR 분야의 능력을 향상시키며, CleanCap® 유사체와 같은 독점 기술을 활용합니다.
이번 결정은 또한 Maravai가 유럽 시장에 진출하는 것을 의미하며, 이는 여러 제품 라인에서 성장을 촉진할 것으로 예상됩니다. Officinae Bio의 CEO인 Davide De Lucrezia는 Maravai의 핵산 생산 부문 내에서 팀을 계속 이끌 것입니다.
Maravai LifeSciences (NASDAQ: MRVI) a finalisé l'acquisition de l'activité ADN et ARN de Officinae Bio. Cette acquisition intègre les plateformes de conception d'ARNm activées par IA d'Officinae Bio avec les capacités de fabrication de substances médicamenteuses de Maravai et TriLink BioTechnologies, offrant une expertise complète et des technologies novatrices. Cette intégration vise à accélérer la phase d'optimisation des séquences d'ARNm et à faire progresser les essais cliniques et la fabrication commerciale.
Officinae Bio, basé à Venise, en Italie, utilise une plateforme numérique propriétaire pour accélérer le prototypage de candidats médicaments à base d'ARNm, facilitant des tests rapides de diverses combinaisons d'analogues de coiffage, de modifications chimiques et de conceptions de séquences. L'acquisition renforcera les capacités de Maravai dans le domaine des médicaments de nouvelle génération, en particulier dans l'ARNm et le CRISPR, en tirant parti de technologies propriétaires telles que les analogues CleanCap®.
Ce mouvement marque également l'entrée de Maravai sur le marché européen avec une empreinte de fabrication, ce qui devrait stimuler la croissance dans plusieurs lignes de produits. Le PDG d'Officinae Bio, Davide De Lucrezia, continuera de diriger l'équipe au sein du segment de Production d'Acides Nucléiques de Maravai.
Maravai LifeSciences (NASDAQ: MRVI) hat die Übernahme des DNA- und RNA-Geschäfts von Officinae Bio abgeschlossen. Diese Übernahme integriert die KI-gestützten mRNA-Designplattformen von Officinae Bio mit den Herstellungsfähigkeiten von Arzneistoffen von Maravai und TriLink BioTechnologies und bietet umfassende Expertise und neuartige Technologien. Diese Integration zielt darauf ab, die Phase der mRNA-Sequenzoptimierung zu beschleunigen und klinische Tests sowie die kommerzielle Herstellung voranzutreiben.
Officinae Bio, mit Sitz in Venedig, Italien, nutzt eine proprietäre digitale Plattform, um die Prototypenerstellung von mRNA-Arzneikandidaten zu beschleunigen und ermöglicht schnelle Tests verschiedener Kombinationen von Kappenanaloga, chemischen Modifikationen und Sequenzdesigns. Die Übernahme wird die Fähigkeiten von Maravai im Bereich der Arzneimittel der nächsten Generation, insbesondere in mRNA und CRISPR, verbessern und proprietäre Technologien wie CleanCap®-Analoga nutzen.
Dieser Schritt markiert auch den Eintritt von Maravai in den europäischen Markt mit einer Produktionspräsenz, die voraussichtlich das Wachstum in mehreren Produktlinien vorantreiben wird. Der CEO von Officinae Bio, Davide De Lucrezia, wird weiterhin das Team im Nucleic Acid Production-Segment von Maravai leiten.
- The acquisition enhances Maravai's mRNA sequence-optimization and manufacturing capabilities.
- Entry into the European market with a manufacturing footprint.
- Potential for accelerated growth across multiple product lines post-pandemic.
- Integration challenges with Officinae Bio's AI-driven tools and platforms.
Insights
This strategic acquisition marks a significant transformation for Maravai LifeSciences, positioning the company at the intersection of AI-driven drug development and established manufacturing capabilities. The integration of Officinae Bio's AI platform with Maravai's TriLink division creates a unique value proposition in the mRNA therapeutics market.
The deal's strategic importance stems from three key factors:
- Technology Integration: Combining Officinae's AI-driven sequence optimization with TriLink's CleanCap® technology creates a comprehensive platform that could significantly reduce drug development timelines and costs. This integration addresses a critical bottleneck in mRNA drug development - the time-consuming process of sequence optimization.
- European Market Entry: The acquisition provides Maravai with its first European manufacturing footprint, a important strategic advantage in the $39.7 billion global mRNA therapeutics market. This presence will enable closer collaboration with European biotech companies and potentially accelerate market share growth in the region.
- Competitive Positioning: The deal strengthens Maravai's position in the post-pandemic mRNA market by offering an end-to-end solution from sequence design to manufacturing. This vertical integration could lead to increased customer retention and higher margins through operational synergies.
The acquisition's timing is particularly strategic as the mRNA therapeutics field expands beyond vaccines into areas such as cancer treatment and rare diseases. The AI-driven approach to sequence optimization could significantly reduce development costs and accelerate time-to-market for new therapies, potentially leading to increased demand for Maravai's services.
While financial terms weren't disclosed, the acquisition's value lies in its potential to enhance Maravai's competitive position in the rapidly evolving nucleic acid production market. The integration of AI capabilities could lead to improved operational efficiency and potentially higher margins through reduced development cycles and increased success rates in drug development programs.
Officinae Bio's AI-driven sequence optimization expands Maravai's family of brands, enabling rapid, cost-effective nucleic acid therapy development
“We are thrilled to bring Officinae into the Maravai family, where their talented team will add cutting-edge AI-driven sequence design and seamless e-commerce to our TriLink Discovery business. Together, we intend to accelerate the field of next-generation medicines in mRNA and CRISPR, using best-in-class chemistries, processes, and proprietary technologies like CleanCap® analogs,” said Trey Martin, CEO of Maravai LifeSciences. “This acquisition also marks our first move into the very important European marketplace with a manufacturing footprint. This market access will fuel our growth across multiple product lines in the post-pandemic era.”
Davide De Lucrezia, Chief Executive Officer and co-founder of Officinae Bio commented, "Joining forces with Maravai and TriLink allows us to extend our expertise in AI-driven tools for more customers to accelerate their development and to identify candidate sequences with fewer errors. Along with TriLink's decades of chemical and biological manufacturing experience, we can now supercharge the design-build-test-learn cycle for our customers."
Davide will continue to lead the Officinae Bio team, now a business within Maravai’s Nucleic Acid Production segment.
To learn more about Maravai's portfolio and its products and services, visit https://www.maravai.com/.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics and cell and gene therapies companies.
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
About Officinae Bio
Officinae Bio is a global leader in the advancement of biologically designed therapeutics through groundbreaking innovations in AI-enabled methodologies for nucleic acid manufacturing. The company is dedicated to pioneering research in gene-modified cell therapy, gene therapy, and RNA therapeutic development with cutting-edge tools and platforms.
DNA Platform
The Vulcanus DNA synthesis platform creates high-precision DNA libraries with exceptional control over variant representation, accelerating lead discovery through targeted sequence exploration with smart mutant libraries.
RNA Platform
The Mercury RNA platform generates libraries of precisely engineered untranslated regions (UTRs), optimizing efficacy and safety through enhanced translational efficiency and tissue-specificity.
Forward-looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224396160/en/
Media Contact: Liz Robinson
CG Life
trilink@cglife.com
Investor Contact: Deb Hart
Maravai LifeSciences
ir@maravai.com
Source: TriLink BioTechnologies
FAQ
What does the MRVI acquisition of Officinae Bio mean for shareholders?
How will the Officinae Bio acquisition impact MRVI's market presence?
What technologies are integrated through MRVI's acquisition of Officinae Bio?
What is the strategic importance of MRVI acquiring Officinae Bio?
Who will lead Officinae Bio after its acquisition by MRVI?
What are the potential challenges MRVI might face with the Officinae Bio acquisition?
